Senegal
Tuberculosis profile
Population  2012 14 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.7 (1.2–4.8) 20 (8.8–35)
Mortality (HIV+TB only) 0.48 (0.4–0.54) 3.5 (2.9–3.9)
Prevalence  (includes HIV+TB) 30 (15–50) 219 (108–368)
Incidence  (includes HIV+TB) 19 (16–22) 137 (113–163)
Incidence (HIV+TB only) 1.7 (1.4–2) 12 (9.9–14)
Case detection, all forms (%) 65 (55–79)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 8 448 (72) Relapse 538 (49)
Smear-negative 1 567 (13) Treatment after failure 141 (13)
Smear-unknown / not done 188 (2) Treatment after default 181 (17)
Extrapulmonary 1 524 (13) Other 232 (21)
Other 0 (0)      
Total new 11 727   Total retreatment 1 092  
           
Other (history unknown) 0        
Total new and relapse 12 265   Total cases notified 12 819  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 2.3    
Age < 15 209 262 221
Laboratories 2012
Smear (per 100 000 population) 0.8
Culture (per 5 million population) 1.1
Drug susceptibility testing (per 5 million population) 0.7
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 85   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 76  
Retreatment 68  
TB/HIV 2012 Number (%)
TB patients with known HIV status 10 048 (78)
HIV-positive TB patients 882 (9)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 793 (90)
HIV-positive TB patients on antiretroviral therapy (ART) 561 (64)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 426  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 2.1 (0.69–4.9) 17 (7–31)
MDR-TB cases among notified pulmonary
TB cases
220 (70–500) 180 (76–340)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 25 (<1%) 113 (10%) 147
Laboratory-confirmed MDR-TB cases 1 24 27
Patients started on MDR-TB treatment     32
Financing TB control 2013
National TB programme budget (US$ millions) 6
% Funded domestically 33%
% Funded internationally 67%
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-20 Data: www.who.int/tb/data